A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Head and Neck Cancer Clinical Trial

Official title:

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01185158
• Other study ID #: 11588A
• Status: Completed
• Phase: Phase 2
• Start date: May 2002
• Est. completion date: November 2010

Study information

• Verified date: November 2023
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out what effects (good and bad) ZD1839 has on one's squamous cell head and neck cancer. The research is being done because currently no effective treatment exists for metastatic (spread of cancer cells from one area of the body to another) or recurrent squamous cell cancer of the head and neck. The purpose of this study is to find out if ZD1839 can shrink tumors or cause tumors to stop growing for a period of time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: November 2010
• Est. primary completion date: August 2004
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed squamous cell carcinoma of the head and neck incurable by surgery or radiation
• Patients must have measurable disease, defined as at least on e lesion that can be accurately measured in the one dimension (longer diameter to be recorded) as greater then or equal to 20mm with conventional techniques or as greater than or equal to 10mm with computed tomograpy (CT) scan.

Therapeutic history that includes the Following:

• No prior EGFR-based therapy for recurrent disease
• No chemotherapy or irradiation with the 28-day period preceding entry to the study
• Eastern Cooperative Oncology Group (ECOG)performance Status 0-2 (kamofsky >59%)

Patients must have normal organ and marrow function as defined below:

• leukocytes >3,000ml
• absolute neutrophil count 1,500/ml
• platelets 100,000/ml
• total bilirubin within normal institutional limits
• AST(SGOT)ALT(SGPT) <2.5 X institutional upper limits of normal
• Creatinine <1.5

Exclusion Criteria:

• Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical in situ.
• Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, ketoconazole, erythromycin, clarithromycin, atorvastatin, cimetidine, ametidine, amitriptyline, imipramine, verpamil, tamoxifen, chlorpromazine, amiodorone, chloroquine, St. John's Wort
• Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy
• Incomplete healing from previous oncologic or other major surgery Patients may not be receiving any other investigational agents
• History of allergic reactions attributed to compound of similar chemical or biologic composition to ZD 1839
• Uncontrolled intercurrent illness
• Pregnancy or breast feeding (women of child -bearing potential

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Head and Neck Cancer

Intervention

Drug:
• ZD1839 (IRESSA)
ZD1839: 250mg/day po or via g-tube Q 24 hours

Locations

Country	Name	City	State
United States	The University of Chicago Medical Center	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the activity of 250mg of ZD1839 administered as a single agent to patients with recurrent or metastatic or both recurrent and metastatic head and neck cancer.		2 -5 years
Secondary	To demonstrate the effectiveness of ZD 1839 as an inhibitor of epithelial growth factor (EGFR) phosphorylation, MAP kinase activation, and vascular endothelial growth (VEGF) secretion in metastatic head and neck cancer.		2-5 years

External Links

•   The University of Chicago Comprehensive Cancer Center Web page